Frontiers in Medicine
Cure8 research brief
Why This Matters
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Who Should Pay Attention
Clinicians and researchers studying biomarkers or biologic response in Crohn’s disease; patients on or starting infliximab or vedolizumab who are interested in emerging monitoring tools.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This was a single-centre, exploratory longitudinal cohort (39 patients starting infliximab or vedolizumab, plus 10 controls) reported in Frontiers in Medicine. Six serum miRNAs were quantified by qPCR at the first and fourth infusions and compared to clinical, CRP, fecal calprotectin and endoscopic scores.
The authors found reduced miR-21-5p and miR-146b-5p in CD versus controls; baseline miR-146b-5p inversely predicted post-induction CRP independent of baseline severity; and post-induction miR-424-5p correlated with concurrent inflammation. A post-hoc signal linked miR-106a-5p changes to penetrating disease.
Next steps and caution The paper frames these findings as hypothesis-generating and calls for prospective independent validation before clinical use. Because the study is single-centre with a small sample and exploratory analyses (including post-hoc testing), the reported miRNAs are candidate biomarkers rather than established tests.
Keep In Mind
This is an exploratory, single-centre study with a small sample size and some post-hoc analyses. The authors explicitly state prospective independent validation is needed before clinical translation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Medicine
PublisherFrontiers Media SA
AuthorsLuisa Bertin, Lara Giraldi, Camilla Cavagna +8 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 13, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...